CD47 and myelodysplastic syndrome: In preclinical models of AML and myelodysplastic syndromes (MDS), it could be demonstrated that the blocking of CD47 enhances antitumor response [12,13] and that the anti-CD47 antibodies stimulate ADCP, promoting priming and memory response of CD8 T cells [14].